All News
Filter News
Found 622 articles
-
Sanofi delivers 2018 business EPS growth of 5.1% at CER
2/7/2019
Net sales were €8,997 million, an increase of 3.5% on a reported basis, 3.9%(3) at CER and 2.6% at CER/CS (4).
-
Regeneron Reports Fourth Quarter and Full Year 2018 Financial and Operating Results
2/6/2019
Regeneron Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year 2018 and provided a business update.
-
Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
1/7/2019
Companies select two clinical-stage bispecific antibodies for ongoing collaboration
-
Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference
1/7/2019
Regeneron Pharmaceuticals, Inc. will provide a strategic business update to the investor community at the 37th Annual J.P. Morgan Healthcare Conference
-
Harbour BioMed Appoints Atul Deshpande, Ph.D. MBA, Chief Strategy Officer and Head of U.S. Operations
1/4/2019
Company also promotes Xiaoxiang Chen, MD, to Chief Development Officer, and Mai-Jing Liao, Ph.D., MBA to Chief Business Officer
-
United Neuroscience Names Peter Powchik, M.D, Executive Vice President of Research & Development
12/21/2018
United Neuroscience (UNS), a clinical-stage biotech company pioneering a new class of medicine to treat and prevent brain disorders, today announced the appointment of Peter Powchik, M.D., to the newly created position of Executive Vice President of Research & Development effective Jan. 1, 2019.
-
Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
12/1/2018
100% overall and 80% complete response rate in 10 patients with relapsed or refractory follicular lymphoma treated with 5 mg or more of REGN1979
-
ODYSSEY OUTCOMES Investigators Highlight at AHA that Praluent® (alirocumab) Injection Was Associated with Fewer Deaths from Any Cause
11/11/2018
Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL
-
New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial
11/7/2018
Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)
-
FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis
11/6/2018
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable.
-
Biopharma companies set to release financial reports next week have reported positive news in recent months.
-
Nearly two weeks after the U.S. Food and Drug Administration approved Sanofi and Regeneron’s Dupixent as an add-on maintenance therapy for moderate to severe asthma, the France-based company reported a surge in sales for the medication in its most recent quarterly report.
-
Sanofi Q3 2018 Performance Confirms Return to Growth
10/31/2018
Third-quarter sales(3) growth led by Specialty Care and Vaccines with strong support from Emerging Markets
-
EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
10/25/2018
First trial in non-proliferative diabetic retinopathy to show both a reduction in vision-threatening complications and in development of diabetic macular edema
-
The FDA approved Sanofi and Regeneron’s Dupixent (dupilumab) as an add-on maintenance therapy for patients with moderate-to-severe asthma. The approved group is age 12 years and older with either an eosinophilic phenotype or with an oral corticosteroid-dependent asthma.
-
FDA Approves Asthma Indication for Dupixent® (dupilumab)
10/19/2018
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration has approved Dupixent® (dupilumab
-
Kevzara® (sarilumab) Data at the 2018 ACR/ARHP Annual Meeting Provide Additional Insight on Safety and Efficacy in Rheumatoid Arthritis
10/19/2018
Among 13 Alliance presentations, a late-breaker poster will highlight potential for IL-6 levels to serve as a biomarker to help predict treatment response
-
FDA approves asthsma indication for Dupixent® (dupilumab)
10/19/2018
The U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.
-
Shares of Regeneron jumped more than 5 percent Monday after the company announced that its blockbuster drug Dupixent (dupilumab) hit the mark in two Phase III trials studying the drug as a treatment for adults with inadequately-controlled chronic rhinosinusitis with nasal polyps.
-
Dupixent® (dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients with Chronic Rhinosinusitis with Nasal Polyps
10/16/2018
Dupixent significantly reduced nasal polyp size, nasal congestion severity and need for systemic corticosteroids and/or surgery